

Special Issue

The Molecular Pathways Involved in Atopic Dermatitis: Implications for Targeted Therapy

Message from the Guest Editor

Atopic dermatitis is one of the most common immune-mediated diseases worldwide, and its prevalence has increased in recent decades. Today, atopic dermatitis is recognized as a disease occurring in predisposed individuals with a compromised skin barrier function. After decades of treatment that is reliant on classical immunosuppressive drugs, atopic dermatitis is now more adequately treated with targeted therapies that aim to block or modulate the key inflammatory pathways responsible for the persistent skin inflammation seen in severe atopic dermatitis. Current standard therapies block the signaling axis of Interleukin (IL)-4 and IL-13, Janus kinases (JAK), and IL-31. Despite this significant advancement, a more detailed understanding of the inflammatory pathways involved in atopic dermatitis is crucial for various objectives, including the discovery of severity markers, clinical response markers, and therapeutic failure markers. This Special Issue aims to encourage studies that uncover the inflammatory pathways of atopic dermatitis and ultimately shed light on the development of new clinical and laboratory markers, as well as new therapeutic targets.

Guest Editor

Prof. Dr. Ciro Martins Gomes
Faculty of Medicine, University of Brasília, Brasília 70910-900, Brazil

Deadline for manuscript submissions

closed (31 March 2026)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/240221

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.